The patent for the drug is held by Pharmacyclics for three to four
more years in India. Pharmacyclics was globally acquired by US giant
AbbVie in 2015 in a massive USD21 billion deal. Natco's latest move is
consistent with its earlier launches and challenging the patents held
on anti-cancer drugs by multinational drug companies.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/natco-launches-cut-price-versions-of-cancer-drug-ibrutinib-in-india/articleshow/72894811.cms
No comments:
Post a Comment